The Use of Non-Invasive Tests to Characterise the Total Baseline Population in the Phase 3 Essence Trial
Laurent Castera1,2; Kristiane Aasen Engebretsen3; George Boon-Bee Goh4,5; Elisabetta Bugianesi6; Burak Demirel3; Tomáš Koller7; Niels Krarup3; Michelle T. Long3; Philip Newsome8,9; Cláudia Oliveira10; Vlad Ratziu11; Mary E. Rinella12; Michael Roden13,14,15; Giada Sebastiani16,17; Arun J. Sanyal18; on behalf of the ESSENCE study group